Mortality, incidence, and microbiological documentation of ventilated acquired pneumonia (ventilator associated pneumonia (VAP)) in critically ill patients with COVID-19 or influenza
Authors' conclusion
In patients ventilated for either COVID-19 or influenza VAP and COVID-19 were associated with a higher risk of mortality.
Study context
- Population
- Intensive care units (ICU) patients on invasive mechanical ventilation for at least 48 h for COVID-19 or influenza, 11 ICUs of the French OutcomeRea network, 2008–2021
- Participants
- 585 patients · 11 ICUs
- Exposure
- COVID-19 vs influenza in ventilated ICU patients; VAP vs no VAP
- COVID-19n = 503
- Influenzan = 82reference
- Outcome
- Mortality related to VAP
- Follow-up
- Day 60
Methodological detailsmulticentre, observational
- Multicentre
- Observational
Main finding
As reported in the abstract
Day-60 mortality
Adjusted hazard ratio (95% CI)P value
VAP vs No VAP
1.77(1.36–2.30)
P < 0.01COVID-19 vs Influenza
2.22(1.34–3.66)
P < 0.01Observational data: associations, not effects.
Further findings
VAP incidence, all VAP episodes
P < 0.01
Patients developing VAP
- Patients developing VAP: 232 patients developed 375 VAP episodes
VAP microorganisms (% of VAP episodes), COVID-19 vs flu
- Gram-positive cocci 29.6% vs 23.5% (p < 0.01)
- Staphylococcus aureus 19.9% vs 11.8% (p = 0.25)
- Gram-negative bacilli 84.2% vs 79.4% (p = 0.47)
- COVID-19 and flu respectively
Original publication
Mortality, incidence, and microbiological documentation of ventilated acquired pneumonia (VAP) in critically ill patients with COVID-19 or influenza. Ann Intensive Care. Published 30 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →